Meng Jiange

All filings by Meng Jiange on record concern Genscript Biotech Corporation. We count 28 filings; the first trade dates from 18 April 2019 and the latest from 4 June 2026.

On the open market, the record shows 5 purchases worth €156k and 14 sales worth €10.9M. The totals do not cover 2 filings with an undisclosed amount. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. 2026 to date brings 1 purchase and 1 sale.

A typical purchase (the median) is worth €54k. On 3 out of 4 purchases, another insider of the same company was buying within the same 30 days. Such overlaps are known as a cluster signal: distinct people reaching the same decision at about the same time. After 3 purchases with a full 90-day history, the hit rate stands at 0% and the median 90-day move at -2.7%. These figures describe past trades and do not predict future prices.

The newest entry dates from 10 June 2026: an open-market purchase, in Genscript Biotech Corporation. Typically, a trade is published a median of 3 days after it takes place. The shorter that gap, the sooner other investors can see what insiders have done. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. This summary is built from HKEX disclosures alone and does not predict where the share price will go.